Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

We report a single institution phase II study of gemcitabine 1200 mg m(−2) i.v. on days 1 and 8 and capecitabine 1300 mg m(−2) twice daily on days 1–14 of each 3-week cycle in patients with metastatic renal carcinoma. Patients had a WHO performance status of 0, 1 or 2. Of the 21 enrolled patients, 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Waters, J S, Moss, C, Pyle, L, James, M, Hackett, S, A'Hern, R, Gore, M, Eisen, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410054/
https://www.ncbi.nlm.nih.gov/pubmed/15505625
http://dx.doi.org/10.1038/sj.bjc.6602209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410054/
https://www.ncbi.nlm.nih.gov/pubmed/15505625
http://dx.doi.org/10.1038/sj.bjc.6602209

Ejemplares similares